These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12075361

  • 21. Economic evaluation of different vaccination programmes to prevent congenital rubella.
    Stray-Pedersen B.
    NIPH Ann; 1982 Dec; 5(2):69-83. PubMed ID: 6820478
    [Abstract] [Full Text] [Related]

  • 22. Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions.
    Thompson KM, Odahowski CL.
    Risk Anal; 2016 Jul; 36(7):1297-314. PubMed ID: 25545778
    [Abstract] [Full Text] [Related]

  • 23. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM, Lynette SP, Stefan M, Kai CS, Chew FT, Wah LB.
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
    [Abstract] [Full Text] [Related]

  • 24. Global cost-effectiveness of cataract surgery.
    Lansingh VC, Carter MJ, Martens M.
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [Abstract] [Full Text] [Related]

  • 25. The costs of scaling up vaccination in the world's poorest countries.
    Bishai D, McQuestion M, Chaudhry R, Wigton A.
    Health Aff (Millwood); 2006 Sep; 25(2):348-56. PubMed ID: 16522576
    [Abstract] [Full Text] [Related]

  • 26. Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee On Research Related To Measles and Rubella Vaccines and Vaccination, June 2004.
    Best JM, Castillo-Solorzano C, Spika JS, Icenogle J, Glasser JW, Gay NJ, Andrus J, Arvin AM.
    J Infect Dis; 2005 Dec 01; 192(11):1890-7. PubMed ID: 16267759
    [Abstract] [Full Text] [Related]

  • 27. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK, Botham L, Schoub BD.
    Vaccine; 2006 Jul 17; 24(29-30):5670-8. PubMed ID: 16766096
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D, Baingana F, Kim J.
    J Ment Health Policy Econ; 2008 Sep 17; 11(3):127-33. PubMed ID: 18806302
    [Abstract] [Full Text] [Related]

  • 29. [Cost of tetanus toxoid injection using a jet-injector (Imule) in collective immunization in Senegal: comparison with injection using a syringe and resterilizable needle].
    Schlumberger M, Châtelet IP, Lafarge H, Genêt A, Gaye AB, Monnereau A, Sanou C, Diawara L, Gueye Y, Lang J.
    Sante; 1999 Sep 17; 9(5):319-26. PubMed ID: 10657777
    [Abstract] [Full Text] [Related]

  • 30. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R.
    J Infect Dis; 2005 Sep 01; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
    Giorgi-Rossi P, Merito M, Borgia P.
    Health Policy; 2009 Feb 01; 89(2):225-38. PubMed ID: 18639952
    [Abstract] [Full Text] [Related]

  • 32. Advocacy and resource mobilization for rubella elimination in Guatemala.
    Flores A, Villeda JA, Rodríguez-Fernández R, Chévez AE, Barrera L, Tezaguic R, Cajas C, Oliva LV, Molina J, Castillo-Solórzano C.
    J Infect Dis; 2011 Sep 01; 204 Suppl 2():S598-602. PubMed ID: 21954253
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. WHO Guide for standardisation of economic evaluations of immunization programmes.
    Walker DG, Hutubessy R, Beutels P.
    Vaccine; 2010 Mar 08; 28(11):2356-9. PubMed ID: 19567247
    [Abstract] [Full Text] [Related]

  • 36. [Comparison of cost and benefits of each model for rubella immunization in Japan].
    Terada K, Niizuma T, Daimon Y, Kataoka N.
    Kansenshogaku Zasshi; 2000 Dec 08; 74(12):1012-7. PubMed ID: 11193552
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P, Levine R, Makinen M, Brenzel L, Mitchell V, Milstien JB, Kamara L, Landry S.
    Vaccine; 2008 Dec 02; 26(51):6706-16. PubMed ID: 18952134
    [Abstract] [Full Text] [Related]

  • 39. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A, Ergonul O, Aksaray S, Tuygun N, Esener H, Tanir G, Eren S, Baykam N, Guvener E, Dokuzoguz B.
    Am J Infect Control; 2006 Nov 02; 34(9):583-7. PubMed ID: 17097453
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.